Effective January 1, 2026, Medi-Cal Rx is excluding coverage for GLP-1 medications prescribed for weight loss: [12] Wegovy, Zepbound, Saxenda: Completely removed from the Contract Drugs List for weight loss Ozempic, Mounjaro, Rybelsus: Restricted to Type 2 diabetes onlyweight loss claims will auto-deny Existing prior authorizations end December 31, 2025 Exceptions: Members under age 21 may still qualify via EPSDT Non-weight-loss indications (Zepbound for OSA, Wegovy for cardiovascular) may still get PA approval This does NOT affect Kaiser commercial or employer-sponsored plansonly Medi-Cal members
GLP1, a human hormone with receptors in various human tissues, including the brain's hunger and fullness center, is known to be deficient in people with obesity
Mistake 3: Confusing U-100 with U-40 syringes
Most patients can take daily antihistamines with GLP-1 medications
Ozempic is strictly for diabetes, while Wegovy suits chronic weight management